EPO revokes Copaxone patent, clears path for Mylan
17-09-2020
Chugai abandons patent claim against Nippon Kayaku
12-04-2018
mediaphotos / iStockphoto.com
Mylan has entered a settlement with Genentech and its parent company, Roche, in relation to patents for cancer drug Herceptin (trastuzumab).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Mylan, IPR, Genentech, settlement, Roche, patent, Herceptin, patent infringement, inter partes review, cancer drug, biosimilar
